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Isavuconazole is a novel antifungal drug approved for the treatment of adults with 
invasive aspergillosis and mucormycosis. While azoles as a class effect are known to 
prolong QTc interval, clinical trials have shown that isavuconazole administration may 
cause shortening in a dose- related manner. Here, we assessed the effects of isavu-
conazole on the length of QTc interval. The objective of the study was to describe 
changes in the QTc interval induced by isavuconazole treatment. A total of 26 adult 
patients from 7 hospitals were included. Patients received isavuconazole for the treat-
ment of invasive fungal infection and, in 1 case, for prophylaxis due to QTc prolonga-
tion under fluconazole. Twelve- channel electrocardiograms (ECGs) were performed 
before and during treatment. Out of 26 patients, 24 showed shortening of QTc inter-
val. In patients with QTc shortening, QTc during isavuconazole treatment showed a 
mean decrease of 7.4 ± 5.8% (36.5 ± 38.8 ms, range 7- 202; P = .004), compared to 
pre-isavuconazole ECG. One patient with available long- term follow- up showed 
 further decrease in QTc on days 55 and 110. Apart from 1 case report, these are the 
first data outside controlled clinical trials showing QTc shortening. Knowledge about 
cardiac effects of isavuconazole will serve to better manage the use of concomitant 
medications.
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1  | INTRODUCTION
Isavuconazole is a novel antifungal drug used for the treatment of in-
vasive aspergillosis and mucormycosis in adults. The drug has been 
approved by the US and the European regulatory agencies in 2016. 
While azoles as a class effect are known to prolong QTc interval,1-3 
clinical trials have shown that isavuconazole administration may 
shorten QTc interval in a dose- related manner.4,5
The QT interval is a measure of time in electrocardiograms (ECGs) 
and describes the duration of the cellular action potential.6 Due to its 
variation with heart rate, the QT interval must be corrected before 
interpretation. Bazett’s formula is most commonly applied for this pur-
pose: the QT interval is divided by square root of the RR interval. The 
upper limit of normal corrected QT (QTc) interval by Bazett is 480 ms 
for both males and females.7 QTc increases with age, health status, for 
example, epilepsy8 and diabetes mellitus,9 and electrolyte abnormali-
ties,10 putting patients at risk of arrhythmia, most notably torsade de 
pointes tachycardia.
Here, we assessed the effect of isavuconazole on the QTc interval 
in 26 patients with invasive fungal diseases.
2  | PATIENTS AND METHODS
We observed 26 adult patients from 7 academic hospitals of maxi-
mum care (6 German, 1 Italian). Patients received isavuconazole for 
the treatment of invasive fungal infection (IFI) and, in 1 case, for 
prophylaxis due to QTc prolongation under fluconazole. Twelve- 
channel ECGs were performed before and during treatment.
Data on IFI, underlying disease, co- medication and electrolytes 
were obtained from electronic health records. Determining the QT 
interval adjusted to heart rate (QTc), the Bazett’s correction formula 
(QTc = QT/√RR) was used for all calculations.6
Patients received isavuconazole according to the manufacturer’s 
instruction. One ECG was performed before isavuconazole treatment 
initiation; a second ECG was performed in median 10 days (range 
1- 46 days) after start of treatment. One patient was followed up in the 
long term, that is, on days 19, 55 and 110.
The Student’s t test was used to test whether the means in each 
set of values differed significantly, assuming 2 possible tails as well 
as unequal variance. A P < .05 was defined as statistically significant. 
Values depict the means ± standard deviation.
3  | RESULTS
A total of 26 patients treated with isavuconazole were observed. 
Underlying conditions of the patients included haematological ma-
lignancies (acute and chronic leukaemia, lymphoma, myelodysplastic 
syndrome), prior allogeneic haematopoietic stem cell or solid organ 
transplantation (lung) and other non- malignant chronic diseases, 
that is, diabetes and chronic obstructive pulmonary disease. Two 
patients did not have any underlying disease. Four patients had 
proven mucormycosis, 14 patients had proven/probable pulmonary 
invasive aspergillosis, 1 patient had an aspergilloma, 3 patients had 
a suspected pulmonary IFI without mycological evidence, 1 had 
IFI of the central nervous system and 2 patients were treated for 
candidiasis.
While 24 out of 26 patients showed a shortening of the QTc in-
terval, no changes were found in 2 patients. In those patients with 
QTc shortening, QTc during isavuconazole treatment showed a mean 
decrease of 7.4 ± 5.8% (36.5 ± 38.8 ms, range 7- 202 ms; P = .004), 
compared to pre-isavuconazole ECG (Figure 1). One patient, followed 
up in the long term, showed further decrease in QTc on days 55 and 
day 110 (Figure 2).
All patients received several drugs as co- medication, whereas 
only 7 received co- medication known to influence the QTc in terms 
of prolongation (amiodarone, pentamidine, tacrolimus). Except for 
1 case, patients received the drugs continuously before as well as 
under treatment with isavuconazole. In this single case, treatment 
with tacrolimus was initiated for graft- vs- host disease at day 50 fol-
lowing allogeneic haematopoietic stem cell transplantation. Eight 
F IGURE  1 QTc pre- and under isavuconazole administration. 
A, QTc changes in 26 patients before (pre- Isa) and under treatment 
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patients showed electrolyte abnormalities, mainly hypo- or hyper-
calcaemia. No differences of QTc changes could be found in pa-
tients with electrolyte abnormalities compared to those with normal 
electrolytes.
Only 1 patient had cardiac symptoms at the time of ECG perfor-
mance, that is, torsade de pointes tachycardia. He was first success-
fully treated with magnesium and defibrillation. Thereafter, he was 
switched to isavuconazole to reduce drug- induced long QT to avoid 
further occurrence of torsade de pointes. Isavuconazole led to normal-
isation of symptoms and ECG findings.
4  | DISCUSSION
Isavuconazole is a second- generation azole antifungal approved for 
the treatment of invasive aspergillosis and mucormycosis. We here 
report on its capability of QTc shortening. Apart from one recent case 
report, these are the first data outside controlled clinical trials show-
ing this effect. A contraindication for isavuconazole is thus a known 
familial short QT syndrome (SQTS),11 a very rare autosomal dominant 
inherited channelopathy; published data include only a small number 
of families.12
In a phase I randomised, double- blind trial, 148 healthy individu-
als received isavuconazole 400 and 600 mg (after 2- day loading dose). 
Isavuconazole shortened the QTc interval in dose- related and plasma 
concentration- related manner. Isavuconazole plasma concentration 
and QTc showed a negative correlation: the predicted mean decrease 
in QTc at the mean plasma drug concentration (Cmax) of 200 and of 
600 mg doses were 11.19 and −17.68 ms, respectively. Trang et al re-
port on 1 case of QTc shortening of 145 ms (613- 468 ms).13 Our data 
confirm these observations.
The QT interval is influenced by physiological and metabolic state 
of the patient. Changes may be induced by diverse clinical conditions 
such as diabetes,9 perioperative anaesthetics14 and multiple arrhyth-
mogenic medications, for example, different azole antifungals.1-3 
Isavuconazole is both a substrate and a moderate inhibitor of the 
CYP3A4 isoenzyme.15,16 This should be considered during administra-
tion of co- medication.
In our patient cohort, QT prolonging co- medications were mostly 
administered continuously before as well as during treatment with is-
avuconazole. QTc decreased when isavuconazole was given. One pa-
tient received tacrolimus for graft- vs- host disease following allogeneic 
haematopoietic stem cell transplantation from day 50 on. However, 
he showed a further decrease in QTc while on tacrolimus treatment 
(432- 422 ms). Isavuconazole may often replace other triazoles, typi-
cally prolonging QT, due to microbiological failure or intolerable side 
effects; such switch within the azole class may enhance the observed 
effect of QTc shortening. However, we could not see differences in 
patients with or without prior treatment with azoles or other QT pro-
longing co- medication regarding QTc shortening by isavuconazole. We 
F IGURE  2 Electrocardiograms (ECG) of a patient before (A) and under treatment (B, C) with isavuconazole. Twelve- channel ECG (A/B: 
25 and C: 50 mm/s paper speed) of a patient treated with isavuconazole. A, d0 before treatment: torsade de pointes tachycardia. B, d0 after 
defibrillation and magnesium administration: sinus rhythm, heart rate 79 bpm, QT 409 ms, QTc 469 ms. C, d8 of isavuconazole treatment: sinus 
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conclude that QTc shortening occurred despite ongoing treatment 
with QT prolonging medication and independently of prior medication 
with other triazoles. Due to a high number of concomitant drugs, fur-
ther assessment of the influence of co- medication is precluded in our 
small patient cohort. Drug- drug interactions always need attention in 
critically ill patients who often receive a wide range of drugs.
Electrolyte abnormalities affect the QT interval. Imbalances of 
potassium, calcium and magnesium influence de- and repolarisa-
tion phases of the cardiac action potential in altering the potentials 
across myocyte cellular membranes. In particular, hypercalcaemia may 
shorten, while hypocalcaemia and hypokalaemia prolong the QT in-
terval.10 Some of the observed patients showed alterations in calcium 
and potassium levels. No differences could be found in patients with 
electrolyte abnormalities compared to those with normal electrolytes. 
On the other hand, 1 of the 2 patients without changes in QTc had hy-
pokalaemia on the day of his second ECG, possibly prolonging QTc and 
thus explaining missing QTc shortening by isavuconazole. No other 
patient had hypokalaemia at the time of his second ECG. The impact of 
electrolyte abnormalities on QTc changes remains uncertain.
The second patient without QTc changes did not have electro-
lyte abnormalities at the time of ECG under isavuconazole treatment. 
Regarding co- medication, amlodipine (calcium channel blocker) and 
valsartan (AT II antagonist) were newly prescribed in the time span of 
first and second ECG. While AT II antagonists do not impact cardiac 
de- and repolarisation,17 this is not finally resolved for calcium channel 
blockers.18,19
Limitations of this study are the small number of patients as well 
as the ranges in timing of ECGs during isavuconazole treatment in 
the different patients. Long- term follow- up was only performed in 
a single patient and showed further decrease in QTc under contin-
ued isavuconazole medication. Taking into account its use for severe 
IFI entailing sustained treatment, subsequent studies should assess 
long- term effects of isavuconazole on QTc. However, our findings 
confirm the observation from controlled clinical trials in a real- life 
setting.
Among triazole antifungal agents, QTc shortening by isavuco-
nazole is unique and so far has not been associated with untoward 
cardiovascular events. Knowledge about cardiac effects of isavuco-
nazole will serve to better manage the use of concomitant medica-
tions. Consideration of SQTS is of minor importance as both SQTS and 
isavuconazole prescription are extremely rare issues.
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